Check-Cap Ltd (NASDAQ:MBAI – Get Free Report) saw a large decline in short interest during the month of May. As of May 29th, there was short interest totaling 65,685 shares, a decline of 63.5% from the May 14th total of 180,004 shares. Approximately 0.9% of the company’s shares are sold short. Based on an average trading volume of 73,927 shares, the short-interest ratio is presently 0.9 days.
Analyst Upgrades and Downgrades
Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Check-Cap in a research report on Friday, April 24th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the stock presently has an average rating of “Sell”.
Check Out Our Latest Report on MBAI
Check-Cap Stock Performance
About Check-Cap
Check-Cap Ltd. (NASDAQ: MBAI) is an Israel-based medical technology company focused on non-invasive screening solutions for colorectal cancer. The company develops an ingestible imaging capsule and associated detection system intended to provide a patient-friendly alternative to traditional colonoscopy and CT colonography for colorectal screening and polyp detection.
Check-Cap’s technology centers on a swallowable capsule that acquires images of the colon as it traverses the gastrointestinal tract; external detectors capture the transmitted signals and software reconstructs images for clinical review.
Read More
- Five stocks we like better than Check-Cap
- SpaceX Rings the Bell and Shatters Every Record
- Adobe Stock Just Got Cheaper—Is Wall Street Missing the Story?
- 3 Dividend Stocks Under $50 That Pay You to Wait Out Inflation
- The 127-Gigawatt Problem: Why AI Needs Its Own Power
Receive News & Ratings for Check-Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check-Cap and related companies with MarketBeat.com's FREE daily email newsletter.
